Psychemedics Corporation (PMDI)
OTCMKTS · Delayed Price · Currency is USD
2.100
0.00 (0.00%)
Oct 28, 2025, 4:00 PM EDT
Psychemedics Revenue
In the year 2024, Psychemedics had annual revenue of $19.69M, down -10.92%. Psychemedics had revenue of $4.43M in the quarter ending December 31, 2024, a decrease of -11.46%.
Revenue
19.69M
Revenue Growth
-10.92%
P/S Ratio
0.65
Revenue / Employee
194.90K
Employees
101
Market Cap
12.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.69M | -2.41M | -10.92% |
| Dec 31, 2023 | 22.10M | -3.14M | -12.45% |
| Dec 31, 2022 | 25.24M | 331.00K | 1.33% |
| Dec 31, 2021 | 24.91M | 3.55M | 16.62% |
| Dec 31, 2020 | 21.36M | -16.32M | -43.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Psychemedics News
- 4 months ago - Psychemedics Releases 2025 Workforce Insights Report - GlobeNewsWire
- 5 months ago - Psychemedics Named “Most Innovative Drug Testing Company of the Year” - GlobeNewsWire
- 11 months ago - Psychemedics Corporation Announces Reverse and Forward Stock Split - GlobeNewsWire
- 1 year ago - Psychemedics Corporation Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing - GlobeNewsWire
- 1 year ago - Psychemedics Corporation Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock - GlobeNewsWire
- 1 year ago - Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing - GlobeNewsWire